Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (21066)	5/19/1998 5:42:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 32384

sorry to interrupt the catfight, but I have a question about LGND ... Henry, the 1550 press release was lean on data. Have you heard any more from what was presented yesterday? Also, it sounds like 1550 has a pretty mild side effect profile, and as the press release says, there was no sign of the headaches and lipid abnormalities seen in other retinoids. Any idea of what causes the lipid effects of retinoids? And are those effects caused by the action of a subset of the retiniod receptors? Peter

To: Henry Niman who wrote (21066)	5/19/1998 5:51:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Great news! Extremely non-toxic, even at higher dose levels and does not induce its own metabolism. Now if it is only effective!! >>With limited information from the higher dose levels, Memorial Sloan- Kettering investigators observed no dose-limiting toxicities and observed only minor adverse events in LGD1550 treated patients. The maximum tolerated dose has not been determined. Unlike all-trans retinoic acid, a retinoid approved for the treatment of acute promyelocytic leukemia, LGD1550 does not appear to induce its own metabolism over the dose range tested since blood levels are maintained with continued therapy. <<